Combined Phacoemulsification and Intravitreal Dexamethasone Implant (Ozurdex®) in Diabetic Patients with Coexisting Cataract and Diabetic Macular Edema. [PDF]
J Ophthalmol, 2017 Purpose To investigate the effectiveness and safety of combined phacoemulsification and dexamethasone intravitreal implant in patients with cataract and diabetic macular edema.
Furino C +8 more
europepmc +2 more sources
Secondary ocular hypertension as an adverse effect of treatment with intravitreal dexamethasone implant: A retrospective Swedish cohort study. [PDF]
Acta OphthalmolAbstract Purpose To evaluate the incidence and risk factors for secondary ocular hypertension (SOHT) following intravitreal dexamethasone implants (Ozurdex®) in patients with diabetic macular oedema (DME) and macular oedema secondary to retinal vein occlusion (RVO) in a Swedish cohort.
Abu Ishkheidem I +5 more
europepmc +2 more sources
Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema. [PDF]
Clin Ophthalmol, 2013 To evaluate the efficacy and safety of an intravitreal dexamethasone implant (Ozurdex®; Allergan Inc, Irvine, CA, USA) in patients with persistent diabetic macular edema (DME) over a 6-month follow-up period.
Pacella E +7 more
europepmc +2 more sources
Central Retinal Vein Occlusion treated with Ozurdex: a case report and review of literature
, 2012 Purpose: To describe the retinal changes occurring after Ozurdex(®) (Ozurdex, Allergan, Inc., Irvine, CA) injection and peripheral laser treatment in a case of central retinal vein occlusion (CRVO).
SEMERARO, Francesco +7 more
core +2 more sources
Dexamethasone Implant Migration through an Iris Coloboma
Case Reports in Ophthalmology, 2020 Ozurdex® 0.7 mg (dexamethasone 0.7 mg implant, Allergan, Dublin, Ireland), an intravitreal biodegradable implant, is indicated for cystoid macular edema due to various causes.
Yoav Glidai +2 more
doaj +1 more source
Progression of Eales’ disease post-partum and long-term follow-up: a case report
Journal of Medical Case Reports, 2018 Background Eales’ disease is a difficult to treat idiopathic form of retinal vasculitis. We present such a case with peculiar epidemiology in which the only efficient therapeutic approach in order to maintain functional vision was repeated intravitreal ...
Radu Ivanescu +3 more
doaj +1 more source
Anterior migration of dexamethasone implant in a pseudophakic patient with intact posterior capsule
Indian Journal of Ophthalmology, 2014 Intravitreal application of Ozurdex ® (Allergan, Inc., Irvine, CA, USA) which is a biodegradable, sustained-release dexamethasone implant has been reported to be effective in the treatment of macular edema.
Nilufer Kocak +3 more
doaj +1 more source
A wandering Ozurdex in the anterior chamber
Taiwan Journal of OphthalmologyDexamethasone intravitreal implantation (Ozurdex®, Allergan Inc. Irvine, CA, USA) has been used in the treatment of persistent macular edema (ME) due to various vitreoretinal diseases.
Ching-Tai Chen +2 more
doaj +1 more source
Acta Ophthalmologica, Volume 104, Issue 6, Page e648-e654, September 2026.Abstract Purpose To describe the associations of treated neovascular AMD with the risk of disability, falls, fractures and mood disorders in a large sample representative of the French population. Methods Analyses were based on 77 582 individuals belonging to the ‘Echantillon Généraliste des Bénéficiaires’, a 1/97 random sample of the French population,
Cécile Delcourt +6 more
wiley +1 more source
Intravitreal dexamethasone implant migration to the anterior chamber in an aphakic child
Vision Pan-America, 2013 An 8-year-old girl, who underwent pars plana lensectomy and vitrectomy for non-infectious uveitis, was treated with a dexamethasone intravitreal implant (Ozurdex®, Allergan Inc., Irvine CA), because of the persistence of cystoid macular edema ...
Lourdes de Juan-Marcos +3 more
doaj +1 more source